List of Viltepso drug patents
Viltepso is owned by Nippon Shinyaku.
Viltepso contains Viltolarsen.
Viltepso has a total of 2 drug patents out of which 0 drug patents have expired.
Viltepso was authorised for market use on 12 August, 2020.
Viltepso is available in solution;intravenous dosage forms.
Viltepso can be used as treatment of duchenne muscular dystrophy (dmd) in patients who have a confirmed mutation of the dmd gene that is amenable to exon 53 skipping.
Drug patent challenges can be filed against Viltepso from 2024-08-12.
The generics of Viltepso are possible to be released after 31 August, 2031.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10870676 | NIPPON SHINYAKU | Antisense nucleic acids |
Aug, 2031
(8 years from now) | |
| US9079934 | NIPPON SHINYAKU | Antisense nucleic acids |
Aug, 2031
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 12, 2025 |
| Orphan Drug Exclusivity (ODE) | Aug 12, 2027 |
Drugs and Companies using VILTOLARSEN ingredient
NCE-1 date: 2024-08-12
Market Authorisation Date: 12 August, 2020
Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a confirmed mutation of the dmd gene that is amenable to exon 53 skipping
Dosage: SOLUTION;INTRAVENOUS
VILTEPSO family patents
15
United States
12
Japan
4
European Union
2
Spain
2
Denmark
2
RS
2
Poland
2
Croatia
2
Slovenia
2
Hungary
1
Russia
1
China
1
Canada
1
Korea, Republic of
1
San Marino
1
Cyprus
1
Portugal
1
Taiwan
1
Australia
1
Lithuania
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic